TLDR AKR1D1 controls glucocorticoid levels and receptor activity in liver cells.
The study demonstrated that AKR1D1, a steroid A-ring reductase predominantly expressed in the liver, played a significant role in regulating glucocorticoid availability and receptor activation in human hepatoma cells. Over-expression of AKR1D1 increased glucocorticoid clearance and decreased glucocorticoid receptor activation and target gene expression, while knockdown of AKR1D1 had the opposite effect. Additionally, 5α-reductase inhibitors finasteride and dutasteride did not inhibit AKR1D1 activity. These findings suggested that AKR1D1 could be crucial in regulating both endogenous and exogenous glucocorticoid actions, impacting liver-related physiological and pathophysiological processes.
47 citations,
July 2009 in “Journal of Biological Chemistry” Finasteride helps treat hair loss and prostate enlargement by blocking a specific enzyme.
108 citations,
February 2008 in “The Journal of urology/The journal of urology” Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.
11 citations,
January 2017 in “Journal of Endocrinology/Journal of endocrinology” Female mice with disrupted 5α-reductase 1 had significant metabolic issues, including stress response problems, insulin resistance, liver fat buildup, and obesity.
131 citations,
September 2017 in “Molecular and Cellular Endocrinology” The document concludes that blocking the internal pathways that create androgens might help treat cancers that depend on sex hormones.
59 citations,
November 2018 in “Psychoneuroendocrinology” Lower levels of certain brain chemicals are linked to worse PTSD symptoms in men.
46 citations,
September 2011 in “Journal of Endocrinology” Natural 5α-reduced glucocorticoids might be anti-inflammatory with fewer side effects than current options.
11 citations,
February 2016 in “Current Medicinal Chemistry” New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.
